Compared to the last two record breaking years, the first half of 2022 has been difficult for those life science companies looking to access capital markets, in part because of increased economic and geopolitical uncertainty. Regardless of the challenges, access to capital is critical for the life sciences ecosystem to thrive and to give leaders the runway to manage product development, regulatory challenges, and evolving marketplace for talent, and the rapid pace of technologic innovation.
To empower life sciences leaders as they make critical go-forward decisions, we will discuss recent trends in capital markets such as IPO’s, venture capital and private equity investment, strategic M&A, as well as a look at the fundraising efforts of investors.
This session will also delve into labor considerations and how to leverage talent in a competitive environment, supply chain challenges both domestically and abroad, and trends in FDA approvals and licensing deals.